| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/03/2008 | CA2285552C Solid compositions suitable for oral administration comprising an alkanoyl-l-carnitine magnesium citrate |
| 06/03/2008 | CA2279846C Engineered protein kinases which can utilize modified nucleotide triphosphate substrates |
| 06/03/2008 | CA2263184C Methods and compositions for increasing the anaerobic working capacity in tissues |
| 06/03/2008 | CA2260135C Method for preparing a polydispersed saccharide composition and resulting polydispersed saccharide composition |
| 06/03/2008 | CA2256015C Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
| 06/03/2008 | CA2203237C Aminotetrazole derivatives useful as nitric oxide synthase inhibitors |
| 06/03/2008 | CA2175215C Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| 06/03/2008 | CA2160016C Method of forming oligonucleotides |
| 05/29/2008 | WO2008064353A2 7,8-saturated-4,5-epoxy-morphinanium analogs |
| 05/29/2008 | WO2008064351A2 (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs |
| 05/29/2008 | WO2008064329A1 Therapeutic tetrahydroisoquinoline-based compositions for cancer therapy |
| 05/29/2008 | WO2008064318A2 Peripheral opioid receptor active compounds |
| 05/29/2008 | WO2008064317A1 Lipophilic opioid receptor active compounds |
| 05/29/2008 | WO2008064315A1 Tetralin analogs having sphingosine 1-phosphate agonist activity |
| 05/29/2008 | WO2008064311A2 Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties |
| 05/29/2008 | WO2008064302A2 Methods for reducing circulating glucose levels |
| 05/29/2008 | WO2008064296A1 Method of treating neurological disorders with carbonic anhydrase inhibitors |
| 05/29/2008 | WO2008064274A1 Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses |
| 05/29/2008 | WO2008064265A2 Compounds modulating c-fms and/or c-kit activity and uses therefor |
| 05/29/2008 | WO2008064264A2 In vivo methods for identifying and screening compounds that modulate calstabin binding to a ryanodine receptor |
| 05/29/2008 | WO2008064259A2 Solid dispersion composition comprising fluvastatin |
| 05/29/2008 | WO2008064244A2 Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| 05/29/2008 | WO2008064217A2 Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol and pharmaceutical formulations thereof |
| 05/29/2008 | WO2008064157A1 Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| 05/29/2008 | WO2008064133A1 Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| 05/29/2008 | WO2008064116A2 Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| 05/29/2008 | WO2008064093A2 Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| 05/29/2008 | WO2008064082A2 Methods for rna desilylation |
| 05/29/2008 | WO2008064066A1 Hepatitis c virus inhibitors |
| 05/29/2008 | WO2008064061A1 Macrocyclic peptides as hepatitis c virus inhibitors |
| 05/29/2008 | WO2008064057A1 Macrocyclic peptides as hepatitis c virus inhibitors |
| 05/29/2008 | WO2008064039A2 Prostaglandin prodrugs as ocular hypotensive agents |
| 05/29/2008 | WO2008064036A1 Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators |
| 05/29/2008 | WO2008064018A1 Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| 05/29/2008 | WO2008064015A1 Methods for preserving renal function using xanthine oxidoreductase inhibitors |
| 05/29/2008 | WO2008064011A1 Acridone compounds |
| 05/29/2008 | WO2008064004A2 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
| 05/29/2008 | WO2008063984A2 Allosteric modulators of the a1 adenosine receptor |
| 05/29/2008 | WO2008063943A2 Method and use for increasing efficacy of anti-adhesive compositions in controlling inflammation and pain |
| 05/29/2008 | WO2008063912A1 Substituted pyrazole and triazole compounds as ksp inhibitors |
| 05/29/2008 | WO2008063888A2 Compounds modulating c-fms and/or c-kit activity and uses therefor |
| 05/29/2008 | WO2008063865A2 Biphosphonate inhalant formulations and methods for using the same |
| 05/29/2008 | WO2008063857A2 Antioxidant dietary supplement compositions and methods for maintaining healthy skin |
| 05/29/2008 | WO2008063847A2 Method for treating autism |
| 05/29/2008 | WO2008063842A2 Methods of treating neuropathic pain with agonists of ppar-gamma |
| 05/29/2008 | WO2008063778A2 Synergistic combinations of antineoplastic thiol-binding mitochondrial oxidants and antineoplastic corticosteriods for the treatment of cancer |
| 05/29/2008 | WO2008063772A2 Resolvin d series and protectin d1 mitigate acute kidney injury |
| 05/29/2008 | WO2008063768A2 Compositions and methods for treating metabolic diseases |
| 05/29/2008 | WO2008063766A2 Amorphous ezetimibe and the production thereof |
| 05/29/2008 | WO2008063756A2 Mucosally non-irritative amphotericin b formulations and methods for treating non-invasive fungus-induced mucositis |
| 05/29/2008 | WO2008063752A2 An enzyme regulating ether lipid signaling pathways |
| 05/29/2008 | WO2008063746A1 Method of treatment for inflammatory bowel disease |
| 05/29/2008 | WO2008063714A1 Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| 05/29/2008 | WO2008063712A1 Use of a2a adenosine receptor agonists in the treatment of ischemia |
| 05/29/2008 | WO2008063673A1 Methods and compositions for controlling body weight and appetite |
| 05/29/2008 | WO2008063671A2 Heterobicyclic metalloprotease inhibitors |
| 05/29/2008 | WO2008063670A1 Heterobicyclic matrix metalloprotease inhibitors |
| 05/29/2008 | WO2008063669A1 Heterobicyclic matrix metalloprotease inhibitors |
| 05/29/2008 | WO2008063668A1 Heterobicyclic metalloprotease inhibitors |
| 05/29/2008 | WO2008063667A1 Heterotricyclic metalloprotease inhibitors |
| 05/29/2008 | WO2008063644A1 Method of radio-sensitizing tumors using a radio-sensitizing agent |
| 05/29/2008 | WO2008063639A2 Compositions and methods for preserving cells of the eye |
| 05/29/2008 | WO2008063634A1 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure |
| 05/29/2008 | WO2008063625A2 Pyridine compounds and methods of their use |
| 05/29/2008 | WO2008063609A2 Diimide-based semiconductor materials and methods of preparing and using the same |
| 05/29/2008 | WO2008063603A2 Methods, compositions, and kits for treating pain and pruritis |
| 05/29/2008 | WO2008063600A2 Triazolyl tropane derivatives |
| 05/29/2008 | WO2008063581A2 Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| 05/29/2008 | WO2008063563A2 Methods of treating keratin hyperproliferation disorders using mtor inhibitors |
| 05/29/2008 | WO2008063556A2 Nornicotine for the treatment of pain |
| 05/29/2008 | WO2008063525A1 Compounds for inhibiting mitotic progression |
| 05/29/2008 | WO2008063514A1 Composition for inhibiting nadph oxidase activity |
| 05/29/2008 | WO2008063505A1 Organic compounds |
| 05/29/2008 | WO2008063356A2 Suture-specific coatings for modulated release of biocative agents |
| 05/29/2008 | WO2008063346A2 IL-14α RNA INHIBITORS AND ANTIBODIES TO IL-14α FOR TREATMENT OF AUTOIMMUNE DISEASES AND LYMPHOMAS |
| 05/29/2008 | WO2008063318A2 Betulinic acid, derivatives and analogs thereof and uses therefor |
| 05/29/2008 | WO2008063311A2 Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals |
| 05/29/2008 | WO2008063300A2 Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
| 05/29/2008 | WO2008063287A2 Novel imidazothiazoles and imidazoxazoles |
| 05/29/2008 | WO2008063284A2 Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
| 05/29/2008 | WO2008063211A2 Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| 05/29/2008 | WO2008063165A1 Compounds useful for treating neurodegenerative disorders |
| 05/29/2008 | WO2008063157A2 A nanoparticle-based anticoagulant |
| 05/29/2008 | WO2008063129A1 Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
| 05/29/2008 | WO2008063128A1 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders |
| 05/29/2008 | WO2008063118A1 Improving release of insulin |
| 05/29/2008 | WO2008063116A1 Indozalyl sulphonamide derivatives useful as glucocorticoid modulators |
| 05/29/2008 | WO2008063114A1 Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia |
| 05/29/2008 | WO2008063099A1 Agent and method for preventing and treating intoxication by alcohol-containing liquids and alcohol substitutes |
| 05/29/2008 | WO2008063045A1 Use of an anti-cancer compound |
| 05/29/2008 | WO2008063025A1 Combination drug of cilostazol and ginkgo biloba extracts |
| 05/29/2008 | WO2008062909A1 ENVIRONMENT-RESPONDING siRNA CARRIER USING DISULFIDE-BRIDGED POLYMERIC MICELLE |
| 05/29/2008 | WO2008062908A1 Method for producing particles and particles |
| 05/29/2008 | WO2008062905A2 Heteromonocyclic compound and use thereof |
| 05/29/2008 | WO2008062830A1 Spiroquinone compound and pharmaceutical composition |
| 05/29/2008 | WO2008062770A1 Quinolone derivative or pharmaceutically acceptable salt thereof |
| 05/29/2008 | WO2008062740A1 Nitrogenated fused ring compound and use thereof |
| 05/29/2008 | WO2008062739A1 Pyrazoles and use thereof as drugs |
| 05/29/2008 | WO2008062574A1 Sugar derivative and use thereof |
| 05/29/2008 | WO2008062559A1 Dietary supplement, anti-fatigue agent or physical endurance enhancer, functional food, or cosmetic |